OMER shares jumped after reporting robust earnings and securing a $2.1 billion licensing agreement with Novo Nordisk.
Omeros (OMER) stock soared to a five-year high Thursday following stronger-than-expected second-quarter results for Yartemlea, its treatment for transplant-related thrombotic microangiopathy. The biotech company reported significant demand for the therapy, the only FDA-approved treatment for the condition, driving the rally.
The surge follows a $2.1 billion licensing deal with Novo Nordisk announced Wednesday, which sent OMER shares up 154%. Analysts had anticipated modest growth, but the combination of earnings strength and the blockbuster deal exceeded expectations.
Shares extended gains in early trading, reflecting investor confidence in Omeros’ pipeline and commercial prospects. The stock’s performance marks its highest level since 2020.